circadian rhythm is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-10-18. Numbers and descriptions here follow the published literature rather than marketing material.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Murphy Roths large (MRL/MpJ) is a strain of laboratory mouse developed in 1999 at The Wistar Institute in Philadelphia, Pennsylvania. Originally bred for autoimmune disease research, it was discovered to have remarkable tissue regeneration abilities.
Fatty acids that are required for good health but cannot be made in sufficient quantity from other substrates, and therefore must be obtained from food, are called essential fatty acids. There are two series of essential fatty acids: one has a double bond three carbon atoms away from the methyl end; the other has a double bond six carbon atoms away from the methyl end. Humans lack the ability to introduce double bonds in fatty acids beyond carbons 9 and 10, as counted from the carboxylic acid side. Two essential fatty acids are linoleic acid (LA) and alpha-linolenic acid (ALA). These fatty acids are widely distributed in plant oils. The human body has a limited ability to convert ALA into the longer-chain omega-3 fatty acids — eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which can also be obtained from fish. Omega−3 and omega−6 fatty acids are biosynthetic precursors to endocannabinoids with antinociceptive, anxiolytic, and neurogenic properties.
==== Technical, trades, and vocational schools ==== During the 2010s, the value higher education came under heightened skepticism due to rising costs and disappointing results. According to the Department of Education, people with technical or vocational training are slightly more likely to be employed than those with a bachelor's degree and significantly more likely to be employed in their fields of specialty. By the late 2010s, the United States was facing a shortage of skilled tradespeople, because a majority of high-school students were still aiming for colleges and universities. But things were changing as more and more members of Generation Z considered alternatives to higher education. Career counselors are in extremely high demand; they are not only called for not just appointments invited to career fairs and orientation sessions for new students. With growing numbers of high-school students opting for trade schools and vocational training programs, enrollments in higher education have been falling.
== The Clinical School == The Clinical School offers the A100 six-year standard course (accepting approximately 280 students each year) or the A101 accelerated graduate course (accepting approximately 40 students each year). Admission is extremely competitive, with the offered courses having among the lowest acceptance rates in the university. Around 10% of applicants were accepted to the A100 standard course for 2022 entry, with 22 places for overseas fee-status applicants. Around 3% of applicants were accepted to the A101 graduate course in 2023. On the standard A100 course, students typically enter the clinical school on completion of three years of pre-clinical training. Approximately half of clinical training in Cambridge takes place at the Cambridge Biomedical Campus, with the other half located in regional hospitals and general practices across the east of England. The accelerated A101 Graduate Entry Course leads to the award of MB BChir (Bachelor of Medicine and Bachelor of Surgery) in 4 years, with approximately 40 students in each cohort. This course is designed for those who already hold bachelor's degrees. This course has an intensive 2–year component with a mix of pre-clinical and clinical teaching, students attend the same lectures and practicals as 1st and 2nd year A100 students during the 8 week terms. They complete the Year 4 placements in the holidays and sit both the A100 2nd year and 4th year exams in the second year of their course. Then the cohort integrates with A100 students in their 5th year for the final two years of the course.
=== Adoption by BIPM until 2026 === The IUPAC 1961 definition of the unified atomic mass unit, with that name and symbol "u", was adopted by the International Bureau for Weights and Measures (BIPM) in 1971 as a non-SI unit accepted for use with the SI. From 2026, the BIPM no longer describes it, or other units, as accepted for use with SI; it is listed among a group of "Internationally recognised units that are not decimal multiples or submultiples of SI units".
Sources: en.wikipedia.org
=== Precautions === Metoprolol succinate controlled release (CR)/extended release (XR) plays an important role in the management of Heart Failure with reduced Ejection Fraction (HFrEF) defined by a left ventricular ejection fraction of ≤ 40%. Evidence supports it reduces the incidence of hospitalisation due to cardiovascular events and worsening heart failure when used in combination with other medications in accordance to current prescribing guidelines. Initiating metoprolol in patients with severe heart failure may cause early clinical deterioration and may not be beneficial in some cases, however, MERIT-HF showed that by approximately two months metoprolol reduces mortality and hospitalisations. COMET suggests early mortality risk is more strongly linked to beta-blocker dose reduction or withdrawal during decompensated heart failure, rather than metoprolol initiation itself.. Patients should monitor for swelling of extremities, fatigue, and shortness of breath.. Given that the evidence from the Cochrane Review there is some efficacy of metoprolol as a prevention of atrial fibrillation recurrence but not prominent. Further investigation may require assessing the ongoing benefit. This medicine may cause changes in blood sugar levels or cover up signs of low blood sugar, such as a rapid pulse rate. It also may cause some people to become less alert than they are normally, making it dangerous for them to drive or use machines.
Pescetarianism, which includes fish and possibly other forms of seafood. Pollotarianism, which includes chicken and possibly other poultry. Semi-vegetarianism is contested by vegetarian groups, such as the Vegetarian Society, which states that vegetarianism excludes all animal flesh. In India, eggs are conventionally classified as non-vegetarian; under Food Safety and Standards Authority of India labeling rules, packaged foods containing egg must carry the brown non-vegetarian mark.
== Treatment == Treatment is predominantly preventive. Avoidance of topical phenols and diets low in tyrosine may help. Replacement and repair of damaged tissue is also possible. Hydroquinone-induced exogenous ochronosis is an avoidable dermatosis that is exceedingly difficult to treat. However, some studies show that treatment may be possible with a Q-switched alexandrite (755 nm) laser. Individuals with this disorder are recommended to stop using hydroquinone-containing compounds. Awareness of this is important, as dermatologists may think the symptoms a patient is exhibiting are a melasma, and prescribe a hydroquinone-containing cream.
== Adverse effects == During the trials there were 5 deaths from acute liver failure and 2 other patients were saved from death by receiving a liver transplant. The toxicity of FIAU was notably delayed as the severe effects became apparent after 13 weeks of treatment. The specific toxic symptoms include: fatigue, skin rash, nausea, bone marrow suppression, seizures, pain in the arms and legs, hepatic (liver) failure (with mild jaundice), lactic acidosis (severe accumulation of lactic acid in the blood), pancreatitis, micro versicular steatosis (marked accumulation of the fat within the cells of the liver), myopathy and peripheral neuropathy. The FIAU is a clear example of direct drug-induced mitochondrial toxicity. Besides being incorporated into the viral DNA, FIAU is also incorporated into mitochondrial DNA. As FIAU is inserted into the growing chain of mitochondrial DNA replication. This leads to an inability of mitochondrial DNA polymerase γ to (further) replicate the DNA. There is a lack of DNA to provide ‘instructions’ to the mitochondria, resulting in reduction of mitochondrial respiration and the activity of mitochondrial respiratory complexes. The mitochondria no longer produce sufficient energy, causing lactic acid to form rapidly. The acute liver failure is a direct result of this cascade. The liver is an energy-intensive organ and thus the failure of its cellular power plants will quickly lead to physical decay. But this damage is not limited to only the liver, as mitochondria are found all throughout the body.
Caddisfly silk is silk that is secreted by the silk glands of the caddisfly (Trichoptera), similar to Lepidoptera silkworms (B. mori). The larvae use silk to hunt and defend themselves. The silk's underwater binding properties are a subject of ongoing scientific research. Trichoptera, or caddisfly, larvae use silk to hunt and protect themselves in their aquatic environment. Much like silkworms and other Lepidoptera, this silk protein is excreted by specialized silk glands. The silk’s structure is mostly conserved among many different caddisfly species, and can be used to bind debris including rocks, sticks, twigs and shells, as well as to build nets for catching prey. Caddisflies, which spend the majority of their life cycle in the larval stage, need these casings to protect their underbellies and pupate. Caddisfly silk is very strong and durable. Because their silk must be able to bind to a variety of components while completely submerged in water, it is therefore being studied for potential applications as a waterproof adhesive.
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.